Publication Roadmap Nuclear Medicine Development: Ambitious Plan for 2035

News

Publication Roadmap Nuclear Medicine Development: Ambitious Plan for 2035

After a year of intensive cooperation with experts and stakeholders from the field, the Nuclear Medicine Development Roadmap was officially presented on Monday 21 October 2024 at the EANM 2024 congress in Hamburg. This roadmap represents a crucial step in realising the ambition to make the Netherlands a global leader in nuclear medicine, with the aim of giving patients access to new treatment options, including for conditions for which few options currently exist.

Key recommendations
Within ten years, the new PALLAS reactor for the production of isotopes for medical applications will be commissioned. This offers opportunities for the production of new, different isotopes and it provides independence. This will allow us to start ensuring in the coming years that every patient gets what they need when they need it and optimise the process of valorisation, with new applications finding their way into patient care and the market as soon as possible. ‘ Nuclear medicine involves diagnostic applications such as PET scans and SPECT in many medical specialities on the one hand, and therapeutic applications, especially in oncology, on the other. The roadmap describes which parties need to take which steps to be ready for this innovative step.

The roadmap is now available, download the roadmap here.

Completion of special envoy project
The publication of the roadmap marks the completion of the special envoy process, which began during the EANM Congress in 2023. The roadmap describes steps needed to realise the vision for the nuclear medicine landscape up to 2035.

Working towards the future
After the successful presentation and discussion, the next phase is focused on implementation, where collaboration in the field is essential to achieve the set goals. The roadmap provides clear guidance for all stakeholders. On 8 November 2024, the Roadmap and its follow-up will be presented in the Netherlands, register here.

Collaboration hub of FAST
FAST is committed to making the Netherlands a global leader in nuclear medicine, aiming to provide patients with access to innovative treatments, including for conditions for which few options currently exist. By facilitating strong collaboration within the sector, FAST aims to create a collaborative hub with stakeholders in which knowledge, expertise and resources are pooled. This initiative should lead to acceleration of research and development, so that together we can contribute to better and new perspectives for patients worldwide. Want to know more about our activities in nuclear medicine? Then take a look here.

Marlous Kooijman

Advisor
Do you have a question about FAST? Send an e-mail to info@fast.nl